{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.260","upperLimit":"3.850","value":"1.0900"},{"groupId":"OG001","lowerLimit":"0.487","upperLimit":"4.530","value":"0.5890"},{"groupId":"OG002","lowerLimit":"0.363","upperLimit":"5.580","value":"0.7200"},{"groupId":"OG003","lowerLimit":"0.358","upperLimit":"3.460","value":"0.9470"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"4.370","value":"0"},{"groupId":"OG005","lowerLimit":"0.151","upperLimit":"3.690","value":"0.9020"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"53"},{"groupId":"OG005","value":"38"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Advanced and/or metastatic non-small cell lung cancer with disease progression on or after an immune checkpoint inhibitor-containing regimen and a platinum-containing regimen, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations, and who were not amenable to curative treatment","id":"OG000","title":"Non-small Cell Lung Cancer"},{"description":"Microsatellite instability-high or mismatch repair deficient colorectal cancer that was unresectable or metastatic","id":"OG001","title":"Colorectal Cancer"},{"description":"Recurrent or metastatic cutaneous squamous cell carcinoma that was not curable by surgery or radiation and in second line if refractory or relapsed after a checkpoint inhibitor-containing regimen and radiotherapy was not feasible","id":"OG002","title":"Cutaneous Squamous Cell Carcinoma"},{"description":"Advanced hepatocellular carcinoma after recurrence or failure of an immune checkpoint inhibitor (not applicable in France)","id":"OG003","title":"Hepatocellular Carcinoma"},{"description":"Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent","id":"OG004","title":"Metastatic Castration-resistant Prostate Cancer"},{"description":"Advanced recurrent ovarian cancer after recurrence or failure on the last platinum-based therapy within 6 months","id":"OG005","title":"Ovarian Cancer"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, 30 (+/-5) minutes after nanrilkefusp alfa administration","title":"Nanrilkefusp Alfa Concentration Profile, Cycle 1 Day 1, 30 (+/-5) Minutes After Nanrilkefusp Alfa Administration","type":"SECONDARY","unitOfMeasure":"ng/mL"}